---
title: "ProPhase Labs Announces Uplisting to OTCID Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273564839.md"
description: "ProPhase Labs, Inc. announced its uplisting from the Pink Sheets to the OTCID Market, effective January 22, 2026. This move is expected to enhance trading visibility and liquidity for its shares, positively impacting shareholders. The latest analyst rating for PRPH stock is a Hold with a $0.13 price target. Spark's AI Analyst rates PRPH as Neutral, citing weak financial performance and bearish technicals, but notes potential catalysts from earnings calls and corporate actions. ProPhase Labs has an average trading volume of 1,169,804 and a market cap of $879.2K."
datetime: "2026-01-23T22:55:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273564839.md)
  - [en](https://longbridge.com/en/news/273564839.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273564839.md)
---

# ProPhase Labs Announces Uplisting to OTCID Market

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

An announcement from Prophase Labs ( (PRPH) ) is now available.

On January 22, 2026, ProPhase Labs, Inc. announced that its common stock had been approved for uplisting from the Pink Sheets to the OTCID Market. The move marks a significant step in enhancing the company’s trading venue, which may improve visibility and liquidity for its shares and is likely to be viewed as a positive development by existing and prospective shareholders.

The most recent analyst rating on (PRPH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on Prophase Labs stock, see the PRPH Stock Forecast page.

**Spark’s Take on PRPH Stock**

According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.

Overall score reflects weak financial performance (sharp revenue decline, negative margins, and negative cash flows) and strongly bearish technicals (well below moving averages with negative MACD). Offsetting factors are limited to mixed but potentially impactful earnings-call catalysts (collections and product partnering) and corporate actions that include both upside (strategic transaction potential) and significant risks (delisting/OTC and dilution-related volatility).

To see Spark’s full report on PRPH stock, click here.

**More about Prophase Labs**

**Average Trading Volume:** 1,169,804

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $879.2K

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PRPH.US](https://longbridge.com/en/quote/PRPH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)
- [Generic drug sector seeks policy fixes after Trump tariff threat](https://longbridge.com/en/news/293501714.md)
- [Trump Says US To Exempt Import Tariff On Generic Drugs For Two Years](https://longbridge.com/en/news/293481843.md)